A novel approach to investigate the relationship between @entity308 and changes in sleep-wake regulatory mechanisms used the @entity1154 oxidase inhibitor (MAOI) @entity20919 that is known to suppress @entity1319 ( @entity1319 ) sleep. Sleep architecture and EEG topography during wakefulness and sleep were studied in eight @entity308 @entity1 before and after five weeks of treatment with @entity20919 (30-90 mg/day), which induced a significant alleviation of @entity308 . Theta power (4.75-7.5 Hz) during a 5-min wake EEG prior to sleep increased two-fold during administration of @entity20919 . @entity1319 sleep was almost completely eliminated. This latter effect was compensated by increased duration of stage 2, whereas total sleep time was not shortened. In non- @entity1319 sleep (stages 2, 3, and 4), treatment slightly reduced EEG power between 2.0-6.25 Hz and 8.5-13.75 Hz; power in the 16.75-25.0 Hz band increased. Activity in the delta band (2.0-3.25 Hz) tended to be reduced in the fronto-central derivation, but not in centro-parietal and parieto-occipital derivations. However, the Treatment X Derivation interaction was not significant. These data indicate that in contrast to wakefulness the effects of @entity20919 treatment on the EEG in non- @entity1319 sleep were small. Rank correlation analyses revealed no association between the antidepressant treatment response and the changes in sleep and EEG power spectra during administration of @entity20919 .

Different effects of @entity20919 treatment on EEG topography in waking and sleep in @entity308 XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity308 :: ('MESH:D003866', 'Disease') :: ['depressive symptoms', 'depressed', 'depression'] @entity20919 :: ('MESH:D010624', 'Chemical') :: ['phenelzine'] @entity1154 :: ('CHEBI:25375', 'Chemical') :: ['monoamine'] @entity1319 :: ('MESH:D015835', 'Disease') :: ['REM', 'rapid-eye-movement']
@entity1 :: (9606,Species) :: ['patients']
